HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Comparative effects of cyproterone acetate or a long-acting LHRH agonist in polycystic ovarian disease.

Abstract
A randomized cross-over study was done to compare the therapeutic efficacy of cyproterone acetate (CPA, 50 mg/day orally) and a depot preparation of the LHRH superagonist (D-Trp6 LHRH 3 mg i.m. once a month) in 10 patients with polycystic ovarian disease (PCO). The two treatment periods were separated by 6 months. Both treatments resulted in marked clinical improvement. In response to CPA treatment, basal plasma gonadotropin, estradiol, estrone, testosterone and androstenedione levels significantly decreased. In response to D-Trp6 LHRH, both basal and stimulated gonadotropin levels were completely suppressed after 3 weeks of treatment. After initial elevation on day 2, plasma ovarian steroid levels fell into the castrate range, without any change in dehydroepiandrosterone sulfate levels. Urinary 3 alpha-androstanediol excretion decreased significantly. In patients with PCO, LHRH-A induced more complete gonadotropin inhibition than did CPA. However, following cessation of either therapy, the disease rapidly recurred.
AuthorsG Schaison, B Couzinet
JournalHormone research (Horm Res) Vol. 28 Issue 2-4 Pg. 169-74 ( 1987) ISSN: 0301-0163 [Print] Switzerland
PMID2969860 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Androgens
  • Delayed-Action Preparations
  • Luteolytic Agents
  • Triptorelin Pamoate
  • Estrone
  • Gonadotropin-Releasing Hormone
  • Cyproterone Acetate
  • Estradiol
  • Luteinizing Hormone
  • Cyproterone
Topics
  • Adult
  • Androgens (blood)
  • Clinical Trials as Topic
  • Cyproterone (analogs & derivatives, therapeutic use)
  • Cyproterone Acetate
  • Delayed-Action Preparations
  • Estradiol (blood)
  • Estrone (blood)
  • Female
  • Gonadotropin-Releasing Hormone (analogs & derivatives, therapeutic use)
  • Humans
  • Luteinizing Hormone (metabolism)
  • Luteolytic Agents (therapeutic use)
  • Polycystic Ovary Syndrome (drug therapy)
  • Random Allocation
  • Triptorelin Pamoate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: